Tests a combined treatment for acute myeloid leukemia that has returned after transplant
Tests camrelizumab, azacitidine and donor lymphocytes in people with relapsed leukemia.
Plain-language title generated from the registry record
Registry title: PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Key facts
- Where
- Suzhou, ChinaSee the site
Where in China
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital of Soochow University
- Trial code
- NCT05772273
- Record updated
- 2 September 2026
- Original description
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantationRead full original descriptionShow less
Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
Inclusion: Patients with a diagnosis of AML relapse after allogeneic hematopoietic stem cell transplantation; Adequate organ function; Be able to understand and sign informed consent; Age 18 to 60 years old; Serum pregnancy test for females of childbearing potential that is negative within one week prior to initiation of first dose of treatment. Female patients of childbearing potential and sexually active males must agree to use a highly effective method of contraception throughout the study and for at least 90 days after the last dose of assigned treatment; ECOG performance status ≤ 1; Known HLA-matched donor without contraindications to donate; Life expectancy > 3 months.
Exclusion: Prior treatment with anti-PD-1, anti-PD-L1, or DLI; Diagnosis of anther malignant disease; Known active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B (HBV) or C (HCV) or Corona Virus Disease 2019(COVID-19); Uncontrolled systemic fungal, bacterial, or viral infection; Known or suspected hypersensitivity to PD-1 inhibitor or azacytidine; Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures; Suspected or proven acute or chronic GVHD; Proven central nervous system leukemia; HLA loss positive; Participation in another clinical study within 3 months.